rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    LUCD
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Lucid Diagnostics Inc (LUCD) Q3 2026 Earnings Call Highlights: Medicare Reimbursement ...
      Nov 12Yahoo FinanceLUCD
      What Lucid Diagnostics (LUCD) Said on Its Q3 Earnings Call
      Nov 12Yahoo FinanceLUCD
      Lucid Diagnostics Inc. Q3 2026 Earnings Call Summary
      Nov 12Yahoo FinanceLUCD
      Lucid Diagnostics earnings missed, revenue fell short of estimates
      Nov 12Investing.comLUCD
      Lucid Diagnostics Inc. (LUCD) Reports Q3 Loss, Lags Revenue Estimates

      Lucid Diagnostics (LUCD) delivered earnings and revenue surprises of 0.00% and -24.81%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

      Nov 12Yahoo FinanceLUCD
      Lucid Diagnostics Recognized as a GenomeWeb Best Place to Work for Second Consecutive Year

      Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it has been named a GenomeWeb 2026 Best Places to Work honoree, marking its second consecutive year in the annual program recognizing top workplaces across the life sciences research, diagnostics and precision medicine sectors.

      Nov 5Yahoo FinanceLUCD
      Lucid Diagnostics to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
      Nov 4Yahoo FinanceLUCDPAVM
      Lucid Diagnostics Announces Publication of Landmark 12,000-Patient Real-World EsoGuard® Study
      Nov 3Yahoo FinanceLUCD
      Lucid Diagnostics to Hold Third Quarter 2026 Business Update Conference Call and Webcast on November 12, 2026
      Oct 29Yahoo FinanceLUCDPAVM
      12 Health Care Stocks Moving In Friday's Intraday Session
      Oct 23BenzingaBOLTLUCD
      Cancer-Screening Test Developer Jumps 28% as Medicare Payments Begin

      Detailed price information for Lucid Diagnostics Inc (LUCD-Q) from The Globe and Mail including charting and trades.

      Oct 23The Globe and MailLUCDPAVM
      12 Health Care Stocks Moving In Friday's Pre-Market Session
      Oct 23BenzingaALZNLUCDPAVM
      PAVmed subsidiary Lucid Diagnostics raises $15 million in preferred stock sale
      Oct 22Investing.comLUCDPAVM
      12 Health Care Stocks Moving In Thursday's After-Market Session
      Oct 22BenzingaLUCDPAVM
      Lucid Diagnostics raises $15 million through Series C preferred stock sale
      Oct 22Investing.comLUCD
      Lucid Diagnostics Begins Receiving Medicare Reimbursement for EsoGuard® and Closes $15 Million Financing
      Oct 22Yahoo FinanceLUCDPAVM
      Lucid Diagnostics Faces Nasdaq Minimum Bid Price Noncompliance

      Detailed price information for Lucid Diagnostics Inc (LUCD-Q) from The Globe and Mail including charting and trades.

      Oct 17The Globe and MailLUCD
      Lucid Diagnostics advances Medicare payment pathways for tests
      Sep 22Investing.comLUCD
      Lucid Diagnostics Advances Multiple EsoGuard® and EsoCheck® Payment, Billing and Coding Pathways

      Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced advances in multiple payment, billing, and coding pathways for its EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell Collection Device, following three public meetings held last week.

      Sep 22Yahoo FinanceLUCDPAVM

      This is the newest page. Registered accounts read further back.